# Clinical Trials Data KRAS - Document 4

# Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

## Clinical Trial: https://clinicaltrials.gov/study/NCT01380795

"eligibilityCriteria": "Inclusion Criteria:\n\n1. men and women\n2. age over 18 y.o.\n3. signed informed consent form.\n4. Patients barriers of Non-small Cell Lung Cancer Metastatic\n5. chemotherapy non yet begun\n6. patients barrier of CTC\n7. Research for mutation of EGFR and Kras made on the primitive tumor\n8. Man and woman old enough to procreate under effective contraceptives\n\nExclusion Criteria:\n\n1. small cells bronchial cancer\n2. Non metastatic bronchial cancer\n3. Absence of detectable CTC at the patient\n4. Private individuals of freedom or under tutelage (including legal guardianship)\n5. Incapacity to sign the inform consent form or psychiatric, behavioural disorders or geographical situation precluding the follow-up of the protocol\n6. Pregnancy, lactating or refusal of the contraception for women",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The criteria state "Research for mutation of EGFR and Kras made on the primitive tumor." This implies that the research \*is\* performed as part of the trial qualification. It doesn't exclude patients based on the \*presence\* of a KRAS mutation. Therefore, having a KRAS mutation would \*\*not\*\* automatically exclude a patient from the trial. They would be tested for it as part of the screening process.